These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12824806)

  • 21. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
    Nannan Panday VR; Hoetelmans RM; van Heeswijk RP; Meenhorst PL; Inghels M; Mulder JW; Beijnen JH
    Cancer Chemother Pharmacol; 1999; 43(6):516-9. PubMed ID: 10321513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.
    Jung C; Bogner JR; Goebel F
    Eur J Med Res; 1998 Sep; 3(9):439-42. PubMed ID: 9737891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.
    Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    Eur J Cancer; 1999 Dec; 35(13):1809-15. PubMed ID: 10673996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HIV protease inhibitors for the treatment of Kaposi's sarcoma].
    Grosso G; Sgadari C; Barillari G; Toschi E; Bacigalupo I; Carlei D; Palladino C; Baccarini S; Malavasi L; Moracci G; Leone P; Chiozzini C; Monini P; Ensoli B
    Recenti Prog Med; 2003 Feb; 94(2):69-74. PubMed ID: 12908373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy.
    Bottieau E; Colebunders R; Schroyens W; Van Droogenbroeck J; De Droogh E; Depraetere K; De Raeve H; Van Marck E
    Acta Clin Belg; 2000; 55(2):97-101. PubMed ID: 10881375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children.
    Pensieroso S; Romiti ML; Palma P; Castelli-Gattinara G; Bernardi S; Freda E; Rossi P; Cancrini C
    AIDS; 2006 Sep; 20(14):1893-6. PubMed ID: 16954733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
    Carleo MA; Di Martino F; Del Giudice A; Gargiulo M; Parrella G; Rosario P; Sangiovanni V; Viglietti R; Esposito V; Chirianni A
    In Vivo; 2015; 29(1):133-6. PubMed ID: 25600542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Waters LJ; Nelson MR
    Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.
    Sgadari C; Monini P; Barillari G; Ensoli B
    Lancet Oncol; 2003 Sep; 4(9):537-47. PubMed ID: 12965274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors.
    Tavel JA; Miller KD; Masur H
    Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes in HIV antiretroviral prescribing practices in the United States.
    Vu QM; Shouse RL; Brady K; Brooks JT; Weiser J
    Int J STD AIDS; 2020 Jan; 31(1):22-29. PubMed ID: 31793389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.